How long does it take for resistance to Apelvis-Piqray to develop during use?

Alpelisib (Alpelisib) - Piqray, as the first oral targeted drug targeting PIK3CA mutations, has high hopes in the treatment of breast cancer. However, just like the common problem faced by most targeted drugs, the emergence of drug resistance is still inevitable. Although the specific time when drug resistance occurs varies between individuals, overseas clinical experience and observations show that most patients may gradually show signs of weakening treatment response within months to a year after receiving Piqray treatment. The reason for this phenomenon may stem from the remodeling of the PI3K pathway, or may be related to adaptive changes in the tumor microenvironment and the activation of other signaling pathways.

The occurrence of drug resistance does not mean that treatment has completely failed, but it does indicate that clinical strategies need to be adjusted. In some studies, it has been found that patients who are resistant to apelvis may develop escape mechanisms of tumor cells from the inhibitory effect of PI3Kα, such as secondary mutations of PIK3CA, reactivation of the AKT pathway, or compensatory enhancement of the MAPK pathway. These changes allow tumor cells to maintain their ability to survive and proliferate under inhibitory pressure. In order to delay the emergence of drug resistance, it is generally recommended in clinical practice to use Piqray in combination with hormonal therapy such as fulvestrant, and to closely monitor the dynamic changes of the tumor in order to identify the trend of reduced treatment effect as early as possible.

In addition to biological mechanisms, patient compliance is also a key factor affecting the time of drug resistance. During long-term medication, if the medication is stopped or the dose is reduced due to side effects such as hyperglycemia, rash, etc., it may also indirectly affect the persistence of the drug effect and shorten the time for the emergence of drug resistance. Therefore, standard management of side effects and reasonable dosage adjustment are particularly important. In practical applications, the development of genetic testing technology has also provided strong support for identifying resistance mechanisms. Once mutations or activation of signaling pathways other than PIK3CA are discovered, clinicians can consider replacing the target drug or try to combine other pathway inhibitors for supplementary treatment.

Reference materials:https://www.piqray.com/